1. Mass Tort Defense: Core Structural Elements
Mass tort defense operates under distinct procedural and strategic constraints that reshape how counsel approaches liability, evidence, and settlement. The consolidation of hundreds or thousands of claims in a single proceeding means that individual case facts often yield to common issues, statistical evidence, and group-level negotiation tactics that would not appear in bilateral litigation. Defendants face pressure to manage inconsistent factual records, conflicting expert opinions, and the risk that adverse rulings on common questions can cascade across the entire docket.
From a practitioner's perspective, the early phase of mass tort defense often determines whether the defendant can establish a coherent narrative about causation, product design, or conduct standards that will resonate across the consolidated group. Courts typically bifurcate discovery and motions into common-issue and individual-issue tracks, which means defendants must invest heavily in establishing defensible positions on shared legal and factual questions before individual case-specific disputes arise. This front-loaded strategy differs sharply from single-plaintiff litigation, where counsel may defer certain positions until discovery reveals the opposing party's specific allegations.
| Feature | Mass Tort | Individual Litigation |
| Number of Claimants | Hundreds to thousands | One or few |
| Forum Consolidation | MDL or class action (centralized) | Single court or scattered venues |
| Discovery Scope | Common issues first; individual discovery later | Full bilateral discovery from outset |
| Settlement Leverage | Group settlement matrices; systemic risk | Bilateral negotiation; case-specific value |
| Precedent Impact | Adverse rulings affect entire docket | Limited spillover to other cases |
2. Mass Tort Defense: Liability and Causation Challenges
Defendants in mass tort proceedings confront causation theories that may rest on statistical associations, regulatory violations, or design defects rather than individualized proof of harm. The burden of proof and the sufficiency of evidence to establish liability often become contested at the motion stage before trial, creating opportunities for defendants to narrow the scope of surviving claims through summary judgment or Daubert challenges to expert testimony. However, courts may permit plaintiffs to proceed on theories that would face skepticism in individual cases, particularly when the consolidated proceeding involves large populations and epidemiological or toxicological evidence.
Regulatory context frequently intersects with mass tort liability. A defendant's compliance or non-compliance with FDA, EPA, or OSHA standards may not resolve the underlying tort claim, but regulatory history often becomes central to discovery disputes and expert testimony. Defendants must distinguish between regulatory approval (which may not preclude tort liability) and actual knowledge of risk, a distinction that shapes both motion practice and settlement positioning. In practice, these disputes rarely map neatly onto a single rule, and courts may weigh regulatory compliance differently depending on whether the claim rests on failure to warn, design defect, or manufacturing defect.
Common Causation and Specific Causation Separation
Mass tort proceedings typically require defendants to address both common causation (whether the product or conduct can cause the alleged injury in the general population) and specific causation (whether it caused injury to each individual plaintiff). Defendants often succeed in narrowing the case by challenging common causation through expert evidence, which can eliminate entire subcategories of claims if the scientific foundation is deemed insufficient. Courts apply rigorous scrutiny to causation testimony, particularly in cases involving pharmaceutical, toxic exposure, or medical device claims, where the intersection of regulatory approval and scientific uncertainty creates complex evidentiary issues.
The timing of causation challenges matters significantly in mass tort defense strategy. Early motions to exclude or limit plaintiff expert testimony can reduce the number of viable claims before expensive individual discovery begins. Defendants should evaluate whether the case involves novel causation theories or well-established scientific principles, as this distinction affects both the strength of Daubert challenges and the likelihood that settlement negotiations will occur before trial.
3. Mass Tort Defense: Procedural Navigation in Consolidated Forums
Consolidated mass tort proceedings, whether through MDL transfer or class certification, impose procedural requirements that differ from traditional civil litigation. In federal MDL proceedings, a single judge oversees all related cases transferred from multiple district courts, creating uniform rulings on discovery, motion practice, and sometimes settlement frameworks. Defendants must coordinate responses across multiple jurisdictions and adapt to procedural orders that may prioritize settlement over traditional trial preparation, reflecting the practical reality that mass tort cases rarely proceed to individual trials.
New York state courts also consolidate mass tort claims through coordinated proceedings or class actions under New York Civil Practice Law and Rules Article 9. The procedural framework in New York courts emphasizes early identification of common issues and may require defendants to address class certification motions before full discovery proceeds. Defendants should recognize that certification denials are often appealed, creating extended periods of uncertainty about the scope and structure of the litigation. This procedural fork, where certification timing and appellate review can reshape the case before trial, means defendants must prepare for both consolidated and individual claim scenarios simultaneously.
Discovery and Expert Disclosure in Consolidated Proceedings
Discovery in mass tort cases typically follows a phased approach: common-issue discovery occurs first, focusing on the defendant's knowledge, design process, testing, and regulatory communications. Individual discovery follows, addressing each plaintiff's exposure history, medical records, and causation-specific evidence. Defendants must produce voluminous documents related to product development, marketing, and safety communications, and courts often impose strict deadlines for expert disclosure and rebuttal expert designation. The scope of document production in mass torts often far exceeds single-case discovery, requiring defendants to implement sophisticated document management systems and privilege review protocols.
Expert testimony carries heightened significance in mass tort defense because a single expert's opinions may apply to hundreds of claims. Defendants should invest early in identifying and retaining experts who can withstand Daubert scrutiny and address both common and specific causation issues. The timing of expert reports is often compressed in consolidated proceedings, and delays in expert designation can result in sanctions or preclusion, limiting the defendant's ability to respond to plaintiff theories.
4. Mass Tort Defense: Settlement Structures and Risk Management
Settlement in mass tort cases frequently occurs through structured agreements that establish claim values, eligibility criteria, and payment schedules rather than individual bilateral negotiations. Defendants negotiate settlement matrices that categorize claims by injury severity or exposure level, allowing for predictable resolution costs and finality across the docket. These settlement frameworks require defendants to accept that individual case values may diverge significantly from what bilateral negotiation would produce, reflecting the leverage dynamics of consolidated litigation and the defendant's interest in achieving global resolution.
The relationship between mass tort defense and related practice areas such as federal extortion defense or other specialized litigation arises when defendants face allegations of misconduct beyond the core product or conduct claim. Defendants should evaluate whether settlement structures adequately address collateral legal exposure, including potential criminal referrals, regulatory enforcement, or derivative shareholder claims. Understanding how the mass tort resolution interacts with other legal fronts allows defendants to assess total risk exposure and negotiate settlement terms that provide meaningful closure.
Settlement Approval and Judicial Oversight
Courts exercise significant oversight of mass tort settlements, particularly in class actions and MDL proceedings where judicial approval is required. The court evaluates whether the settlement is fair, reasonable, and adequate, considering factors such as the strength of the defendant's liability exposure, the adequacy of the settlement fund, and the fairness of the allocation mechanism. Defendants must prepare detailed settlement documentation, including claim valuations, eligibility definitions, and dispute resolution procedures. The settlement approval process can extend for months, during which the defendant remains exposed to ongoing litigation costs and reputational risk.
In New York courts, settlement approval typically requires notice to class members or affected parties and an opportunity for objection or opt-out. The court may hold a fairness hearing where plaintiffs' counsel and individual claimants can challenge the settlement terms. Defendants should anticipate that settlement negotiations will include discussions about claims administration, dispute resolution procedures, and potential reopeners if claim volumes or values exceed projections. Strategic considerations at the settlement stage include evaluating whether to include non-monetary relief, such as product modifications or enhanced warnings, which may affect long-term liability exposure.
Concrete next steps for defendants navigating mass tort defense include documenting the company's knowledge and decision-making processes related to the product or conduct at issue, preserving all communications with regulators and internal safety assessments, and evaluating the strength of causation defenses through early expert consultation. Defendants should also assess whether parallel regulatory investigations or criminal exposure exist, as these may affect settlement timing and structure. Early coordination between defense counsel, insurance carriers, and company management ensures that litigation strategy aligns with business objectives and risk tolerance, and that settlement authority is clearly established before negotiation intensifies.
11 May, 2026
